Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-specific chimeric antibodies in stage IV cancer
NCT06674538Phase 1Enrolling by invitation
- Sponsor
- Moonshot Antibodies
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- IgG Antibodies, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Moonshot antibodies in breast cancer, colon cancer, esophageal cancer and 12 more, sponsored by Moonshot Antibodies. Primary endpoint: Adverse Events at 6 months. Started Dec 2024; status: enrolling by invitation.
02
Drugs
Moonshot antibodies
03
Conditions
breast cancercolon canceresophageal cancerkidney cancerlung cancer
Beyond the preview
Go deeper on NCT06674538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674538.